CA2886442A1 - Generation de nouvelles cellules beta du pancreas - Google Patents

Generation de nouvelles cellules beta du pancreas Download PDF

Info

Publication number
CA2886442A1
CA2886442A1 CA 2886442 CA2886442A CA2886442A1 CA 2886442 A1 CA2886442 A1 CA 2886442A1 CA 2886442 CA2886442 CA 2886442 CA 2886442 A CA2886442 A CA 2886442A CA 2886442 A1 CA2886442 A1 CA 2886442A1
Authority
CA
Canada
Prior art keywords
seq
peptide
amino acid
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2886442
Other languages
English (en)
Inventor
Claresa LEVETAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/662,209 external-priority patent/US8911776B2/en
Priority claimed from US13/662,253 external-priority patent/US9133440B2/en
Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en
Priority claimed from US13/662,245 external-priority patent/US9511110B2/en
Application filed by Individual filed Critical Individual
Publication of CA2886442A1 publication Critical patent/CA2886442A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA 2886442 2012-09-27 2013-09-26 Generation de nouvelles cellules beta du pancreas Abandoned CA2886442A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261706225P 2012-09-27 2012-09-27
US61/706,225 2012-09-27
US13/662,253 2012-10-26
US13/662,209 US8911776B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 2012-10-26
US13/662,245 2012-10-26
US13/662,232 2012-10-26
US13/662,253 US9133440B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,232 US20140120560A1 (en) 2012-10-26 2012-10-26 Generation of new pancreatic beta cells
US13/662,245 US9511110B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
PCT/US2013/061947 WO2014052611A1 (fr) 2012-09-27 2013-09-26 Génération de nouvelles cellules bêta du pancréas

Publications (1)

Publication Number Publication Date
CA2886442A1 true CA2886442A1 (fr) 2014-04-03

Family

ID=50388965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2886442 Abandoned CA2886442A1 (fr) 2012-09-27 2013-09-26 Generation de nouvelles cellules beta du pancreas

Country Status (5)

Country Link
EP (1) EP2900691A4 (fr)
JP (1) JP2015533821A (fr)
AU (1) AU2013323462A1 (fr)
CA (1) CA2886442A1 (fr)
WO (1) WO2014052611A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104614523B (zh) * 2014-12-19 2016-09-21 成都永安制药有限公司 结核分枝杆菌tb-sa抗体酶联免疫法检测试剂盒及其制备方法
WO2017063657A1 (fr) * 2015-10-14 2017-04-20 Phlogo Aps Antagoniste peptidique dérivé de l'il-1ra
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
AU6049899A (en) * 1998-09-17 2000-04-17 Trustees Of Columbia University In The City Of New York, The Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2609667C (fr) * 2005-05-25 2011-02-22 Curedm, Inc. Peptides, derives et analogues associes, et leurs methodes d'utilisation
NZ583679A (en) * 2007-08-30 2012-05-25 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
WO2009049222A1 (fr) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions et procédés d'utilisation du récepteur de peptide pro-îlot humain

Also Published As

Publication number Publication date
AU2013323462A1 (en) 2015-04-23
EP2900691A4 (fr) 2016-04-20
WO2014052611A1 (fr) 2014-04-03
JP2015533821A (ja) 2015-11-26
EP2900691A1 (fr) 2015-08-05

Similar Documents

Publication Publication Date Title
US7714103B2 (en) Peptides, derivatives and analogs thereof, and methods of using same
JP5960661B2 (ja) 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
US8785400B2 (en) Methods and compositions relating to islet cell neogenesis
US20050197292A1 (en) Compositions and methods for treating T-cell mediated pathological conditions
EP3202415A2 (fr) C1orf32 fusionnée avec le fragment fc pour le traitement de la sclérose en plaques, la polyarthrite rhumatoïde et d'autres maladies auto-immunes
US8911776B2 (en) Generation of new pancreatic beta cells
CA2886442A1 (fr) Generation de nouvelles cellules beta du pancreas
US9511110B2 (en) Generation of new pancreatic beta cells
US9133440B2 (en) Generation of new pancreatic beta cells
US20140120560A1 (en) Generation of new pancreatic beta cells

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180926